Abstract
Concise guidance is lacking for the use of bevacizumab by practicing oncologists. Eight oncologists with experience of bevacizumab were joined by a cardiologist interested in treating hypertension to develop practical guidelines for managing patients receiving bevacizumab, using available clinical data.
Publication types
-
Consensus Development Conference
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Bevacizumab
-
Gastrointestinal Diseases / chemically induced
-
Hemorrhage / chemically induced
-
Humans
-
Hypertension / chemically induced
-
Hypertension / prevention & control
-
Neoplasms / drug therapy*
-
Proteinuria / chemically induced
-
Randomized Controlled Trials as Topic
-
Thromboembolism / chemically induced
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Wound Healing / drug effects
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Vascular Endothelial Growth Factor A
-
Bevacizumab